<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://gate.unigre.it/mediawiki/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=DinahDomingo545</id>
	<title>GATE - User contributions [en]</title>
	<link rel="self" type="application/atom+xml" href="https://gate.unigre.it/mediawiki/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=DinahDomingo545"/>
	<link rel="alternate" type="text/html" href="https://gate.unigre.it/mediawiki/index.php/Special:Contributions/DinahDomingo545"/>
	<updated>2026-05-30T13:19:42Z</updated>
	<subtitle>User contributions</subtitle>
	<generator>MediaWiki 1.35.7</generator>
	<entry>
		<id>https://gate.unigre.it/mediawiki/index.php?title=Buy_JWH-210_Online_Premium_Powder_For_Sale&amp;diff=149014</id>
		<title>Buy JWH-210 Online Premium Powder For Sale</title>
		<link rel="alternate" type="text/html" href="https://gate.unigre.it/mediawiki/index.php?title=Buy_JWH-210_Online_Premium_Powder_For_Sale&amp;diff=149014"/>
		<updated>2026-05-28T19:12:37Z</updated>

		<summary type="html">&lt;p&gt;DinahDomingo545: &lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;When clinical presentation and/or initial DOA testing results are inconclusive, additional testing with LC-QTOF-MS can be valuable and is recommended. SCRAs and other NPS may not be detected by point-of-care DOA tests. In this case, the point-of-care DOA urine screening was not able to detect the synthetic cannabinoid ADB-BUTINAC&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Synthetic cannabinoids have consistently been shown to produce discriminative stimulus effects similar to those [https://cannabinoidsrc4f-adb.com/ 4F ADB] of Δ9-THC (Bannister and Connor, 2018), and MDMB-FUBINACA fully substituted for Δ9-THC (Gamage et al., 2018). The chemical structures of the recent synthetic cannabinoids are unlike that of Δ9-THC, but are largely based on the structure of older synthetic cannabinoids that are known to have substantial abuse liability (Fig. 1). All 5 compounds decreased locomotor activity and produced discriminative stimulus effects similar to those of Δ9-THC, which suggests they may have abuse liability similar to that of Δ9-THC. Subsequent testing identified 5F-ADB to have been present in a total of ten people who had died from unexplained drug overdoses in Japan between September 2014 and December 2014. AMB-FUBINACA produced tremors and may be of increased risk in human recreational users.&amp;lt;br&amp;gt;Michael B Gatch &amp;lt;br&amp;gt;Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/kg. Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the highest dose tested (0.5 mg/kg). Figure 1 shows average horizontal activity counts/10 min as a function of time (0–4 h) and dose of Δ9-TH&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;High resolution mass spectrometry such as LC-QTOF-MS allows the detection and identification of a broad spectrum of recreational drugs, including new psychoactive substances. A point-of-care drugs of abuse (DOA) test was initially performed on the urine of the patient. He confirmed drinking 750 ml energy drink without any further consumption of food and using an e-cigarette from Gaziantep, Turkey 10 seconds before the onset of his first symptoms. He usually smokes a pack of cigarettes a day and sometimes smokes e-cigarettes. Combined with non-specific, transient symptoms, clinical recognition of SCRA intoxication is challenging .&amp;lt;br&amp;gt;Data availability &amp;lt;br&amp;gt;The intensity is plotted against the retention time for both chromatograms, demonstrating the 4F ADB presence and elution profiles of nicotine and ADB-BUTINACA in the analysed vape liquid sample. LC-QTOF-MS Chromatograms of Nicotine (Top) and ADB-BUTINACA (Bottom) in the Vape Liquid used by the patient. The LC-QTOF-MS analysis showed that the e-liquid contained nicotine and ADB-BUTINACA (Fig. 1). Because the point-of-care DOA test is generally not able to detect synthetic recreational drug substances, the liquid of the e-cigarette was thereafter screened using liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) on the Waters™ Xevo G3 QTOF MS system. After eating a light meal and drinking caffeinated sports drinks at the ER, the nausea complaints of the patient were reduced and the patient was discharged hom&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Effects of individual doses were compared to the vehicle control value using a priori contrasts. Response-rate data were analyzed by one-way repeated-measure analysis of variance. Percent drug-appropriate responding was shown only if at 4F ADB least three rats completed the first fixed ratio, whereas all rats are shown for the response rate dat&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Moreover, genetic makeup, physiological conditions (age, gender and ethnicity), environmental influences (diet) and pathological factors (liver diseases, diabetes, and obesity) would further complicate the metabolism of drug&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Separation of compounds was performed on a 2.1 mm×100 mm, 1.7 4F ADB μm particle size ACQUITY Torus™ DIOL analytical column (Waters) with guard cartridge. Measurements were performed by an ACQUITY UPC2 supercritical fluid chromatography system (Waters) coupled with a Xevo TQ-S Triple Quadrupole Mass Spectrometer (Waters). During the death scene examination, multiple cigarette butts without filters were found in an ashtray; also found were alcohol bottles, an unopened box of nebivolol-containing drug, and 18 g of unrecognizable herbal residue in a cigarette box.&amp;lt;br&amp;gt;Victim B also brought &amp;quot;something resembling a drug&amp;quot; (unrecognizable by Witness A) from his cousin (Witness B) in a cigarette box and mixed this substance with their tobacco. The half-maximal effective concentration (EC50) of 4F-MDMB-BINACA is 5.69 nM (2.76–11.0 nM) on CB1, and 0.69 nM (0.30–1.56 nM) on CB2, in vitro half-life (t1/2) is 10.27 min . It is usually available as a powder, liquid (vapor fluid), or herbal plant mixtur&lt;/div&gt;</summary>
		<author><name>DinahDomingo545</name></author>
	</entry>
	<entry>
		<id>https://gate.unigre.it/mediawiki/index.php?title=Simultaneous_Fatal_Poisoning_Of_Two_Victims_With_4F-MDMB-BINACA_And_Ethanol&amp;diff=148639</id>
		<title>Simultaneous Fatal Poisoning Of Two Victims With 4F-MDMB-BINACA And Ethanol</title>
		<link rel="alternate" type="text/html" href="https://gate.unigre.it/mediawiki/index.php?title=Simultaneous_Fatal_Poisoning_Of_Two_Victims_With_4F-MDMB-BINACA_And_Ethanol&amp;diff=148639"/>
		<updated>2026-05-26T07:05:44Z</updated>

		<summary type="html">&lt;p&gt;DinahDomingo545: Created page with &amp;quot;A total of 2 and 3 methamphetamine treated mice fell from the spinning rod 30 min and 2 hr after the administration, respectively. After the first injection, 6 mice of the pos...&amp;quot;&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;A total of 2 and 3 methamphetamine treated mice fell from the spinning rod 30 min and 2 hr after the administration, respectively. After the first injection, 6 mice of the positive control group (methamphetamine, 5 mg/kg, i.p.) showed loss of traction, of which 4 showed tremor. Most of the abnormalities were normalized in synthetic cannabinoid treated mice although those abnormal behaviors remained in methamphetamine treated animals after 2 hr of administration. Brain samples were prepared from the mice after the last administration of test substance&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;When clinical presentation and/or initial DOA testing results are inconclusive, additional testing with LC-QTOF-MS can be valuable and is recommended. SCRAs and other NPS may not be detected by point-of-care DOA tests. In this case, the point-of-care DOA urine screening was not able to detect the synthetic cannabinoid ADB-BUTINAC&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;The findings produce an apparent paradox, since CPP and self-administration predict with high reliability the likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in human&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. It is illegal to sell, distribute, supply, transport or trade the pharmaceutical drug under the Psychoactive Substances Act 2016. The corresponding indole core analogue, 4F-MDMB-BICA (4F-MDMB-BUTICA), has also been widely sold as a designer drug by chemical providers on the internet, first being identified in May 2020. It has been used as an active ingredient in synthetic cannabis products and sold as a designer drug since late 2018. 4F-MDMB-BINACA (also known as MDMB-4F-BINACA using systematic EMCDDA nomenclature or 4F-MDMB-BUTINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family.&amp;lt;br&amp;gt;Fig. &amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Observation item 1st injection 2nd injection 3rd injection 4th injection 5th injection Con. All groups treated with tested synthetic cannabinoids showed decreased weight gain rate in a dose-dependent manner. A total of 5 mice in the JWH-081 (5 mg/kg, i.p.) treated group and 6 mice in the [https://cannabinoidsrc4f-adb.com/ click to investigate] JWH-210 (5 mg/kg, i.p.) treated group showed loss of traction, of which 4 and 5 showed tremor, respectively. Memory retention was measured after the memory acquisition was tested as a probe trial.&amp;lt;br&amp;gt;About Powder JWH-2&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;In the present study, we performed various methods based on animal behavioral testing including FOB test for general behavioral observation, rotarod test, locomotor activity test for motor function evaluation, and water-maze test for learning/memory evaluation. Known for its stability and consistent composition, this compound is frequently utilized by professionals seeking reliable materials for laboratory-based analytical studies. In this study, histopathological evaluation was performed to confirm the possibility of neurotoxicity of the tested substances by hematoxylin and eosin staining method from collected brain samples. In the present study, we evaluated the neurotoxicity of two synthetic cannabinoids (JWH-081 and JWH-210) through observation of various behavioral changes and analysis of histopathological changes using experimental mice with various doses (0.1, 1, 5 mg/kg). Selecting powder JWH-210 demands careful evaluation of purity, legality, and supplier credibility. Prices for research-grade JWH-210 vary significantly based on quantity, purity, and vendor complianc&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;High resolution mass spectrometry such as LC-QTOF-MS allows the detection and identification of a broad spectrum of recreational drugs, including new psychoactive substances. A point-of-care drugs of abuse (DOA) test was initially performed on the urine of the patient. He confirmed drinking 750 ml energy drink without any further consumption of food and using an e-cigarette from Gaziantep, Turkey 10 seconds before the onset of his first symptoms. He usually smokes a pack of cigarettes a day and sometimes smokes e-cigarettes. Combined with non-specific, transient symptoms, clinical recognition of SCRA intoxication is challenging .&amp;lt;br&amp;gt;Data availability &amp;lt;br&amp;gt;The intensity is plotted against the retention time for both chromatograms, demonstrating the click to investigate presence and elution profiles of nicotine and ADB-BUTINACA in the analysed vape liquid sample. LC-QTOF-MS Chromatograms of Nicotine (Top) and ADB-BUTINACA (Bottom) in the Vape Liquid used by the patient. The LC-QTOF-MS analysis showed that the e-liquid contained nicotine and ADB-BUTINACA (Fig. 1). Because the point-of-care DOA test is generally not able to detect synthetic recreational drug substances, the liquid of the e-cigarette was thereafter screened using liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) on the Waters™ Xevo G3 QTOF MS system. After eating a light meal and drinking caffeinated sports drinks at the ER, the nausea complaints of the patient were reduced and the patient was discharged hom&lt;/div&gt;</summary>
		<author><name>DinahDomingo545</name></author>
	</entry>
</feed>